<DOC>
	<DOCNO>NCT01924143</DOCNO>
	<brief_summary>The purpose study evaluate absorption , distribution , metabolism , excretion ( ADME ) single oral dose [ 14C ] TD-9855</brief_summary>
	<brief_title>TD-9855 Mass Balance Study</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>Healthy , nonsmoking male subject healthy , nonsmoking female subject childbearing potential , 18 50 year old , inclusive . Women consider childbearing potential hysterectomy tubal ligation least 2 year postmenopausal ( folliclestimulating hormone [ FSH ] &gt; 40 IU/mL ) Body mass index 19 31 kg/m2 , inclusive , weight least 55 kg Negative hepatitis B , hepatitis C , HIV antibody Have evidence history clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose ) , hematological , endocrine , dermatologic , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease Subjects , opinion investigator , risk suicide risk harm others , score positive CSSRS ( item 2 high ideation ) . Subjects history suicide attempt Any condition possibly affect drug absorption ( e.g. , previous surgery gastrointestinal tract [ include removal part stomach , bowel , liver , gall bladder , pancreas ] ) Infrequent bowel movement ( less per 24 hour ) last 7 day prior Day 1 . Subject unable provide fecal sample prior study drug dose Day 1 Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Fibromyalgia</keyword>
</DOC>